Many promising drug candidates fail in formulation not because of weak pharmacology, but because standard excipients cannot support their development requirements. Modern pharmaceutical pipelines increasingly include molecules with poor aqueous solubility, low physical or chemical stability, limited bioavailability, incompatible processing behavior, or delivery constraints that conventional formulation systems struggle to address. In these cases, the […]